Comparison of Efficacy, Safety and Costs of Recombinant FVIII Products Between On-demand and Secondary Prophylaxis Groups in Haemophilia A Patients

NCT01817868 · clinicaltrials.gov ↗

COMPLETED

Status

73

Enrollment

INDUSTRY

Sponsor class

Conditions

Hemophilia

Interventions

OTHER: Recombinant Factor VIII (Kogenate, BAY14-2222)

Sponsor

Bayer